Looking Forward: HHS 2026 and the Liberation from Regulatory Capture

Reclaiming Scientific Integrity: What to Expect from HHS in 2026. This is a bit more than a wish list.

In 2026, the U.S. Department of Health and Human Services will be unrecognizable to those who remember its years of regulatory capture, statistical opacity, and entrenched methodological rot and bias. Secretary Robert F. Kennedy Jr. has already announced and begun implementing reforms so fundamental that the department is being recast not just as an agency of health governance, but as a trust-repair mechanism. For the first time in decades, the architecture of public health is shifting away from institutional preservation and toward epistemic legitimacy. This is the year HHS begins to work for the people again—not for corporations, not for captured consensus panels, not for proxy interests. It is a celebration of freedom from regulatory capture, and a declaration that data must now prove what officials say is true.

The Inherited Problems

It would be a mistake to frame the current crisis in biomedical credibility as the result of disinformation, as so many technocrats have done. The public’s intuition—that vaccine policy has been manipulated, that environmental factors in autism have been ignored, that chronic disease guidance contradicts observable outcomes, that peer review has become gatekeeping instead of quality control—is not a delusion. It is an indictment. These are not just suspicions. They are pattern recognitions. Americans watched ACIP recommend products for universal use while injuries went uninvestigated. They watched NIH fund psychiatric and behavioral genetics research on autism while ignoring toxicological exposures with plausible mechanistic pathways. They were told to trust public health dashboards that changed case definitions midstream, revised denominators without disclosure, and treated dissent as misinformation. They were right to be skeptical. And now, that skepticism is policy’s starting point.

To rebuild trust, HHS must start from what is known—not what is presumed, or politically acceptable. The reproducibility crisis is now a quantifiable reality. A collaborative replication effort published in Science found that only 36% of peer-reviewed psychology studies could be reproduced when tested independently, even with access to original methods and author guidance PMID: 26315443. The implications go far beyond psychology. When methods are non-transparent, replication is discouraged, and incentives reward novelty over verification, the scientific process itself becomes inverted. HHS’s reforms are grounded in reversing that inversion. Beginning in 2026, NIH grants will require pre-registration of all confirmatory analyses, and applicants will be evaluated not just on novelty or citations, but on their ability to publish reproducible results using open data and code. This realignment of incentives will produce slower, but more durable science—one capable of informing public health policies without collapsing under scrutiny.

Autism

In autism research, HHS will abandon the unidimensional genetic model that has dominated federal funding portfolios. A study across Sweden, Israel, and Australia estimated autism’s heritability at 83%, but the variability depending on population structure and analytic method shows that environment plays a critical role PMID: 28973605. HHS will open the analysis to studying both genetics and environment, and, importantly, the genetic x environment interaction. When environment and g x e found to be significant beyond genetics alone, the conclusion is that ASD risk is modifiable will have support, and medicine must change.

Recognizing that autism risk is modifiable opens the door to credible environmental research. In 2026, NIH and CMS will jointly operate a real-world data platform that integrates insurance claims, EHRs, and wearable data to track exposures and outcomes in real time. The platform will enable precision modeling of developmental timing effects, stratified by demographics, socioeconomic status, and medical history. Autism research will shift from narrative-protective abstraction to testable, exposure-specific models that treat the developing human brain as vulnerable to cumulative toxic load, metabolic disruption, immune dysregulation, and pharmacological insult.

Vaccine Safety

On vaccine safety, the reconstitution of the CDC’s Advisory Committee on Immunization Practices (ACIP) in mid-2025 marks a categorical shift in governance. In prior decades, ACIP operated under layers of procedural legitimacy but functional capture. Members with financial or professional conflicts of interest voted on product recommendations without recusal. Transparency was performative. As of 2026, ACIP’s new rules require public COI declarations, recusals, open voting records, and publication of all evidence tables, underlying datasets, and analytic plans before a vote. This is not cosmetic. It is structural detoxification. The expected impact is twofold: first, vaccine recommendations will better withstand public scrutiny; second, ACIP will once again function as a scientific advisory body rather than a downstream marketing channel.

And in contrast to past years, ACIP members will continue to use the term “risk” openly and brazenly in conjunction with the word “vaccine”

To support this new transparent and vaccine risk aware architecture, HHS will also modernize the Vaccine Injury Compensation Program (VICP). Previously shielded from public accountability by outdated reporting infrastructure and narrow eligibility categories, VICP will publish regular adjudication reports, accept novel injury categories tied to emerging research, and allow re-review of previously denied claims when the evidence base changes. This is not a litigation giveaway. It is an investment in procedural justice, a prerequisite for restoring informed consent in any federally sanctioned immunization program.

NIH or NIEHS might prioritize studies that target the removal of aluminum past the 8 weeks of utility, especially in cases of behavioral changes, eczema, new onset of autoimmunity or asthma, and autism. Let’s see if they dare.

Aluminum

Aluminum pharmacokinetics will no longer be modeled in isolation from human biology. Risk assessments to date have depended on flawed compartment models assuming linear kinetics, rapid excretion, and negligible retention PMID: 22001122. These assumptions have found soundly contested, PMID:29773196, are the effects of aluminum exposure reduction and removal will now be tested. We can expect that HHS will fund both mild and intensive chelation trials in human subjects in 2026, evaluating whether measured reductions in body burden correlate with symptom improvement in eczema, asthma, and autoimmune conditions. These trials will be stratified by baseline burden, with clinical endpoints such as SCORAD for eczema, asthma control test scores, and validated autoimmune disease activity indices. Outcomes like severity and frequency of recurrence (flares) in autoimmunity and asthma will provide robust causal assessment. Biomarkers will include serum aluminum following challenge chelation (e.g., Mosaic Dx), urinary excretion, inflammatory cytokine panels, and gut microbiome signatures. Other metals and toxicants that come out will be tallied. If positive, these trials may open a new chapter in preventive toxicology—one where exposure reduction becomes a medical strategy, not just an environmental goal.

Agency-Wide Vitamin D Policy Reform

This same commitment to evidence-based reform is visible in vitamin D policy. Despite high enthusiasm for supplementation, the VITAL trial—a gold-standard, randomized, placebo-controlled study—showed no major effect of vitamin D on cancer or cardiovascular disease endpoints in a general population PMID: 30415629. This study was fundamentally flawed: Many of these issues pertain to generalizability (inadequate representation of vitamin D-deficient populations, exclusions based on adherence), statistical oversight (lack of multiplicity adjustments, post hoc analyses), and the interpretation of results (misleading claims based on non-significant findings and potential biases in adverse events reporting). These factors call into question the strength of the overall conclusions about vitamin D's impact on cancer and cardiovascular disease prevention.

Because of dosage safety testing we have addressed, vitamin D has been neglected in policymaking. In an ideal 2026, HHS will shift from population-wide deficiency narratives to targeted supplementation based on stratified risk. NIH will fund trials designed by BMI category, latitude, genetic variant, and baseline 25(OH)D. CDC will modernize its nutritional surveillance platforms, with transparent dashboards and downloadable data. CMS will revise coverage determinations so that vitamin D testing and supplementation are reimbursed only when clinical indications and risk profiles warrant it. FDA and USDA will revisit fortification policies to ensure they match actual deficiency risk, not outdated assumptions.

Non-Pharmacologic Infection Control

HHS will also fund high-rigor trials of non-pharmacologic infection control methods. Ideally, these will include HVAC upgrades for school and workplace ventilation, HEPA filtration, upper-room UV-C lighting, and micronutrient optimization (including vitamin C, D, and zinc). In clinics, it could include prescription-based use of iodine, safe dose peroxide and ozone infusions, and others. The objective is to test their capacity to reduce all-cause respiratory infections and other infections, with study arms that compare cost-effectiveness, uptake, and population health outcomes. If these interventions prove superior or complementary to pharmaceuticals, HHS may shift funding from drug-heavy pandemic preparedness plans to environmental resilience and biologically plausible, low-risk interventions that support immune function without generating resistance or toxicity.

Methodological Rigor Entrenchment

These reforms require statistical integrity, and that begins with the architecture of health data. In 2026, the National Center for Health Statistics (NCHS) will complete its transition from the CDC to the newly empowered Office of Strategy. This is more than bureaucratic reshuffling. It is a firewall against model laundering and data laundering. Ideally, The Office of Strategy will convene a task force to sort out the flawed methodology enforced by past administrations and operate a public “Methods Ledger” tracking which surveillance outputs meet replication and transparency standards. All federal studies used to justify public policy will be required to publish pre-specified analytic plans, rationale for model choice, and executable code. Versioned dashboards will be mandatory when case definitions or denominators change, and independent audit teams will review high-impact analyses before release. The goal is to ensure that the public does not have to trust CDC press releases—they can inspect the logic themselves.

Reform of Informed Consent Practices

Enforcement of research ethics will follow a similar model. The Office of Research Integrity (ORI) will ideally be fully consolidated within the Office of Strategy and funded with an explicit mandate to police methodological fraud, data manipulation, and human subjects protection failures. Informed consent will no longer be treated as paperwork. Beginning in 2026, HHS will deploy a randomized audit program targeting IRBs, consent processes, and participant debriefs. Penalties will escalate from corrective action plans to grant ineligibility. Public repositories of consent forms and summary documents will allow researchers and participants to verify what was promised and what was disclosed. This enforcement ladder protects not just participants, but the integrity of the scientific system that relies on their trust.

Healthcare to Wellcare Financing

In financing, HHS and CMS are using real-world policy pilots to reestablish the principle of evidence-based reimbursement. The BALANCE model, set to roll out across Medicaid and later Medicare, will tie GLP-1 weight loss drug coverage to demonstrated health impact: reduced hospitalization, lowered A1C, decreased cardiovascular risk - all with adverse events tracking directly to FDA and CMS. The GLOBE model will tie Part B drug reimbursement to international price benchmarks. If successful, these models will form the basis for a broader shift: CMS will pay for what works, not what is advertised. Coverage decisions will include de-adoption clauses when interventions fail real-world replication or post-marketing surveillance. This is not rationing. It is fidelity to evidence.

All of these directions are consistent with the MAHA agenda, and all are needed. The old guard may claim this agenda undermines science, vaccines, or pharmaceutical innovation. They are wrong. It defends them from erosion by subjecting them to scrutiny that they must survive to remain legitimate. Replication doesn’t slow innovation—it prevents false innovation from becoming entrenched. Transparency doesn’t scare the public—it earns their participation.

This is not a pivot or rebrand. It is a systemic correction. Institutions do not deserve trust. They must build it. In 2025 HHS has already started. 2026 is the year the department becomes audit-capable, consent-enforcing, capture-resistant, and evidence-anchored. A scientific republic must never again be governed by unreplicable authority.

Next in Series: The Metrics That Matter: Designing Gold-Standard Science in Public Health